Sreelatha Anju, Bennett Terry L, Carpinone Emily M, O'Brien Kevin M, Jordan Kamyron D, Burdette Dara L, Orth Kim, Starai Vincent J
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390; and.
Departments of Microbiology and.
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):100-5. doi: 10.1073/pnas.1413764111. Epub 2014 Dec 1.
Vesicle fusion governs many important biological processes, and imbalances in the regulation of membrane fusion can lead to a variety of diseases such as diabetes and neurological disorders. Here we show that the Vibrio parahaemolyticus effector protein VopQ is a potent inhibitor of membrane fusion based on an in vitro yeast vacuole fusion model. Previously, we demonstrated that VopQ binds to the V(o) domain of the conserved V-type H(+)-ATPase (V-ATPase) found on acidic compartments such as the yeast vacuole. VopQ forms a nonspecific, voltage-gated membrane channel of 18 Å resulting in neutralization of these compartments. We now present data showing that VopQ inhibits yeast vacuole fusion. Furthermore, we identified a unique mutation in VopQ that delineates its two functions, deacidification and inhibition of membrane fusion. The use of VopQ as a membrane fusion inhibitor in this manner now provides convincing evidence that vacuole fusion occurs independently of luminal acidification in vitro.
囊泡融合控制着许多重要的生物学过程,膜融合调节失衡会导致多种疾病,如糖尿病和神经紊乱。在此我们表明,基于体外酵母液泡融合模型,副溶血性弧菌效应蛋白VopQ是一种有效的膜融合抑制剂。此前,我们证明VopQ与在酸性区室(如酵母液泡)上发现的保守V型H⁺-ATP酶(V-ATP酶)的V₀结构域结合。VopQ形成一个18 Å的非特异性电压门控膜通道,导致这些区室的中和。我们现在展示的数据表明VopQ抑制酵母液泡融合。此外,我们在VopQ中鉴定出一个独特突变,该突变区分了它的两种功能,即去酸化和抑制膜融合。以这种方式将VopQ用作膜融合抑制剂,现在提供了令人信服的证据,表明体外液泡融合独立于腔内酸化发生。